Amicus Therapeutics (FOLD) Stock Price Down 6.4%
Amicus Therapeutics, Inc. (NASDAQ:FOLD) traded down 6.4% on Monday . The stock traded as low as $13.72 and last traded at $13.96. 4,420,029 shares changed hands during mid-day trading, an increase of 57% from the average session volume of 2,808,526 shares. The stock had previously closed at $14.91.
Several equities research analysts recently weighed in on the company. Zacks Investment Research lowered Amicus Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, December 19th. Leerink Swann restated a “buy” rating and issued a $20.00 target price (up from $17.00) on shares of Amicus Therapeutics in a report on Wednesday, October 4th. Robert W. Baird restated an “outperform” rating and issued a $16.00 target price on shares of Amicus Therapeutics in a report on Monday, September 25th. Bank of America boosted their target price on Amicus Therapeutics from $15.00 to $20.00 and gave the stock a “buy” rating in a report on Wednesday, October 4th. Finally, Goldman Sachs Group restated a “neutral” rating and issued a $17.00 target price on shares of Amicus Therapeutics in a report on Friday, October 6th. One research analyst has rated the stock with a sell rating, three have given a hold rating and six have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $17.81.
The company has a quick ratio of 6.22, a current ratio of 6.32 and a debt-to-equity ratio of 0.39. The stock has a market cap of $2,350.00, a PE ratio of -7.77 and a beta of 1.72.
In other Amicus Therapeutics news, Director Michael Raab sold 10,000 shares of Amicus Therapeutics stock in a transaction that occurred on Thursday, October 12th. The stock was sold at an average price of $14.25, for a total value of $142,500.00. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO John F. Crowley sold 65,581 shares of Amicus Therapeutics stock in a transaction that occurred on Thursday, December 21st. The stock was sold at an average price of $13.51, for a total value of $885,999.31. Following the completion of the transaction, the chief executive officer now directly owns 393,076 shares in the company, valued at $5,310,456.76. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 826,114 shares of company stock worth $11,791,184. Company insiders own 3.40% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the business. Strs Ohio bought a new position in Amicus Therapeutics in the 3rd quarter worth approximately $102,000. Tudor Investment Corp ET AL bought a new stake in shares of Amicus Therapeutics during the second quarter valued at approximately $124,000. Zacks Investment Management bought a new stake in shares of Amicus Therapeutics during the second quarter valued at approximately $145,000. Birchview Capital LP bought a new stake in shares of Amicus Therapeutics during the third quarter valued at approximately $151,000. Finally, Sage Capital Advisors llc bought a new stake in shares of Amicus Therapeutics during the third quarter valued at approximately $154,000.
About Amicus Therapeutics
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.